文献速递慢性肾脏病

国际CKD队列个体水平分析:结局发生率跨国差异显著

A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts.
PubMed 文献 · Kidney Int · 2019-08-30

该研究对iNET-CKD网络中8项CKD队列研究进行个体水平分析,比较CKD进展、ESKD、全因死亡和心血管事件的发生率。总体上CKD进展率为40事件/1000人年(95%CI 39-41),但标准化后各研究间异质性超过92.5%。即使调整年龄、性别、合并症和实验室指标后,基线特征与结局的关联仍因研究组而异,提示需进一步探索不同人群中的特定因素。

要点

  • CKD进展率40/1000人年,ESKD 28/1000人年,死亡41/1000人年,CVD事件29/1000人年。
  • 标准化后各研究间结局发生率异质性高(超过92.5%)。
  • 基线特征与结局的关联在不同队列间存在显著交互作用。

核心结论

  • 即使考虑年龄、性别、合并症和实验室标志物的分布,CKD进展、ESKD、死亡和CVD风险在不同国家间仍存在差异。
  • 研究结果支持需要更好地理解不同人群中解释这种差异的特定因素。

研究设计与样本

  • 对iNET-CKD国际CKD队列网络中8项研究进行个体水平分析。

主要发现

  • 总体CKD进展率为40事件/1000人年(95%CI 39-41),ESKD为28(27-29),死亡为41(40-42),CVD事件为29(28-30)。
  • 标准化率在各研究间高度异质(超过92.5%)。
  • 日本CKD-JAC队列中女性vs男性CKD进展的调整HR为0.44(95%CI 0.35-0.56),乌拉圭NRHP队列为0.66(0.59-0.75)。
  • 美国CRIC队列中基线eGFR每低10单位ESKD的调整HR为2.02(95%CI 1.88-2.17),加拿大CanPREDDICT队列为3.01(2.57-3.53),跨所有研究比较交互作用显著。

临床怎么用

  • 临床中应认识到CKD结局风险存在国家/人群差异,不能简单将单一队列的风险估计外推至其他人群。
  • 需结合本地人群特征评估CKD进展和ESKD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rates of chronic kidney disease (CKD) progression, end stage kidney disease (ESKD), all-cause mortality, and cardiovascular (CVD) events among individuals with CKD vary widely across countries. Well-characterized demographic, comorbidity, and laboratory markers captured for prospective cohorts may explain, in part, such differences. To investigate whether core characteristics of individuals with CKD explain differences in rates of outcomes, we conducted an individual-level analysis of eight studies that are part of iNET-CKD, an international network of CKD cohort studies. Overall, the rate of CKD progression was 40 events/1000 person-year (95% confidence interval 39 - 41), 28 (27 - 29) for ESKD, 41 (40 - 42) for death, and 29 (28 - 30) for CVD events. However, standardized rates were highly heterogeneous across studies (over 92.5%). Interactions by study group on the association between baseline characteristics and outcomes were then identified. For example, the adjusted hazard ratio for CKD progression was 0.44 (95% confidence interval 0.35 - 0.56) for women vs. men among the Japanese (CKD-JAC), while it was 0.66 (0.59 - 0.75) among the Uruguayan (NRHP). The adjusted hazard ratio for ESKD was 2.02 (95% CI 1.88 - 2.17) per 10 units lower baseline eGFR among Americans (CRIC), while it was 3.01 (2.57 - 3.53) among Canadians (CanPREDDICT) (significant interaction for comparisons across all studies). The risks of CKD progression, ESKD, death, and CVD vary across countries even after accounting for the distributions of age, sex, comorbidities, and laboratory markers. Thus, our findings support the need for a better understanding of specific factors in different populations that explain this variation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Orlandi PF, Huang J, Fukagawa M, et al. A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. Kidney Int. 2019. PMID: 31570197. doi:10.1016/j.kint.2019.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。